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Abstract
Background—The coronary artery calcium score (CAC) predicts future coronary heart disease
(CHD) events and could be used to guide primary prevention interventions, but CAC
measurement has costs and exposes patients to low-dose radiation.
Methods and Results—We estimated the cost-effectiveness of measuring CAC and
prescribing statin therapy based on the resulting score under a range of assumptions using an
established model enhanced with CAC distribution and risk estimates from the Multi-Ethnic Study
of Atherosclerosis (MESA). Ten years of statin treatment for 10,000 55-year-old women with high
cholesterol (10-year CHD risk=7.5%) was projected to prevent 32 myocardial infarctions, cause
70 cases of statin-induced myopathy, and add 1,108 years to total life-expectancy. Measuring
CAC and targeting statin treatment to the 2,500 women with CAC>0 would provide 45% of the
benefit (+501 life-years), but CAC measurement would cost $2.25 million and cause 9 radiation-
induced cancers. Treat All was preferable to CAC screening in this scenario and across a broad
range of other scenarios (CHD risk=2.5-15%) when statin assumptions were favorable ($0.13/pill
and no quality of life penalty). When statin assumptions were less favorable ($1.00/pill and
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disutility=0.00384), CAC screening with statin treatment for persons with CAC>0 was cost-
effective (<$50,000/quality-adjusted life-year) in this scenario, in 55-year old men with CHD
risk=7.5%, and in other intermediate risk scenarios (CHD risk=5-10%). Our results were critically
sensitive to statin cost and disutility, and relatively robust to other assumptions. Alternate CAC
treatment thresholds (>100 or >300) were generally not cost-effective.
Conclusions—CAC testing in intermediate risk patients can be cost-effective, but only if statins
are costly or significantly impact quality of life.
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Lowering cholesterol with HMG-CoA Reductase Inhibitors (statins) reduces risk of
cardiovascular disease (CVD) in patients who have not yet suffered a CVD event (i.e.,
primary prevention).1 Using statins in otherwise healthy individuals, however, has financial
costs, may be inconvenient or undesirable to patients for a variety of reasons, and exposes
patients to risks of adverse drug effects.2-4 Patients at higher CVD risk are more likely to
benefit from statins, and current guidelines recommend a more aggressive approach to statin
prescribing in these patients,5 but our ability to predict CVD using traditional risk factors
(e.g., Framingham-based risk equations) is imperfect.6, 7 Whether additional risk
stratification testing might be useful and cost-effective for guiding statin therapy remains
controversial3, 8-10.
The coronary artery calcium score (CAC) is an indicator of coronary atherosclerosis
measured by computed tomography scanning that could be used to guide statin therapy.
While CAC is strongly correlated with traditional risk factors, it provides substantial
additional information about an individual's risk for future coronary heart disease (CHD)
events, including myocardial infarction, angina, and CHD death,11-13 and helps improve risk
classification13 more than other currently available non-traditional risk factors.14
Measurement of the CAC score, however, adds front-end costs and exposes patients to small
doses of ionizing radiation.15 It is unclear when using CAC to guide statin therapy might
provide significant net health benefits to patients, and whether such use would be cost-
effective.
We estimated the costs and effectiveness of using CAC testing to guide primary prevention
with statin therapy using an established decision model that was enhanced with CAC
parameters from the Multi-Ethnic Study of Atherosclerosis (MESA).11, 16 Unlike previous
efforts,17-21 our model carefully accounts for the expected CAC distribution in a range of
specific clinical scenarios16, and provides systematic analyses of CAC testing strategies with
different treatment thresholds (versus simply prescribing statins or not) under a range of
assumptions about statin therapy and CAC scan cost, effectiveness and adverse effects.22
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Overview and Model Structure
The UNC-RTI (University of North Carolina-Research Triangle Institute) CVD Prevention
Model is a state-transition simulation model that can be used to compare incidence of CVD,
mortality, quality of life, and costs with and without a prevention intervention.23, 24 In the
model, a specific clinical scenario is defined by age, sex, and CVD risk factors. Persons with
these characteristics begin in the healthy state then may transition every 12 months. Separate
states explicitly model first and subsequent years after myopathy, angina, and myocardial
infarction (MI), as well as stroke; costs, quality of life and mortality rates differ in each
state. Total costs and quality-adjusted life-years (QALYs) were calculated (discounting at
3%/year for costs and utilities) over a lifetime horizon.
Our primary outcome measure is the incremental cost-effectiveness ratio (ICER), measured
in $/QALY. For illustration purposes, we indicate “preferred strategies” under the
assumption that society is willing to pay up to $50,000/QALY, but continuous ICER values
are provided throughout. Model parameters were varied in one-way and global probabilistic
analyses. Online Supplemental Materials describe the model parameters (Supplemental
Table 1), and provide additional Methods detail. This research did not involve human
subjects or animals and does not require institutional review board approval.
Prevention strategies compared: To scan or not to scan?
The model is used to compare 5 different interventions: 2 strategies where statin prescribing
does not depend on results of a coronary artery calcium (CAC) scan (“Treat None”, and
“Treat All”), and 3 strategies where a CAC scan is ordered (one time only, with attendant
costs and radiation exposure), and statins are prescribed only if the CAC score is above a
given threshold (“Treat if CAC>300”, “Treat if CAC>100”, and “Treat if CAC>0”). Statin
prescribing is assumed to be differential for 10 years, but accrual of costs and quality-
adjusted life-years is simulated across a full lifetime horizon to fully account for the
consequences of a life saved or myocardial infarction prevented by statins during those first
10 years of differential treatment.
Base-case scenarios
Our base-case clinical scenario is a 55-year-old woman with total cholesterol = 221 mg/dl
and high density lipoprotein (HDL) cholesterol = 40 mg/dl (“high cholesterol”), and no
other CHD risk factors (systolic blood pressure = 120 mmHg without medications, no
smoking or diabetes). These risk factors yield an average Framingham-derived 10-year risk
for angina, myocardial infarction, or CHD death 7.5%25 (used for state transition
probabilities along with a stroke risk of 0.9%), and they also determine the CAC score
distribution (see below). Alternate clinical scenarios varying age, sex and overall risk are
also considered.
Based on preliminary results showing sensitivity to statin-related parameters, we present two
base-case statin scenarios in parallel throughout the manuscript. The first assumes that
statins can be obtained at a cost of $0.13/pill (available through $4/month prescribing
Pletcher et al. Page 3






















programs at some large discount retailers26) and that taking a statin pill every day is not
associated with any reduction in quality of life (“favorable statin assumptions”); the second
scenario assumes a higher cost of $1.00/pill (most statin users do not avail themselves of $4/
month programs26) and a quality of life penalty (“disutility”) of .00384 associated with
every year of statin use, which is equivalent to trading away 2 weeks of perfect health to
avoid 10 years on statins27 (“less favorable statin assumptions”). The quality of life penalty
modeled here represents inconvenience, reduction in self-conception of health, and any other
reason why a patient might prefer not to take a pill daily; statin-induced myopathy is
modeled separately.
Coronary artery calcium score testing parameters
Direct CAC scan costs were obtained from the American Medical Association's Relative-
Based Resource Value Scale (RBRVS).28 We added the cost of a physician visit28 for scan
interpretation and average workup costs for incidental non-cardiac findings29, 30 (see
Supplemental Material).
The prevalence of CAC and expected distribution of the CAC score, conditional on CHD
risk factors, is a critical parameter31 that we estimated using a multivariable model derived
from the MESA baseline examination.16 We used this model to estimate the proportion of
scores falling into categories of 0, 1-100, 101-300, and >300, and then to estimate “post-
test” risk for angina, MI and CHD death in these categories using CAC-specific relative
risks from MESA11 and previously described methods.16 We assumed that the risk of stroke
did not vary with CAC.
We assumed an average radiation dose of 2.3 millisieverts (mSv) from each scan,15 and an
excess relative risk (ERR) of 0.001/mSv for all-cause cancer15, 32 (see Supplemental
Material).
Statin assumptions
Along with the cost and disutility assumptions described above, we assumed 1) statin use
triggers 1 additional physician visit and lipid panel per year, 2) standard dose statins are
associated with relative reductions in risk of myocardial infarction (26%; i.e., relative risk =
0.74), angina (26%), stroke (15%), and CHD death (20%)1 (Supplemental Material), 3)
statins cause myopathy2 (with associated cost, mortality and disutility for 1 year,27 and
which then leads to statin discontinuation), and 4) imperfect statin adherence,33 with
discontinuation events occurring immediately. Hepatitis and liver function testing costs were
not included.2, 34 Although there is evidence that statins cause diabetes,4 the cardiovascular
benefits outweigh the risks, at least in the short term,35 and the statin trial results upon which
we base our statin efficacy assumptions account for this effect. Alternate assumptions about
statin-associated cost and health impact from these factors or others are easily simulated by
increasing overall statin cost and disutility.
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Ten years of statin treatment for 10,000 55-year-old women with high cholesterol (10-year
CHD risk=7.5%, stroke risk=0.9%) was projected to prevent 32 lifetime myocardial
infarctions, cause 70 cases of statin-induced myopathy, and add 1,108 years to total life-
expectancy (Treat All vs. Treat None). Targeting statin treatment to the 2,500 women with
CAC>0 (Treat if CAC>0) would provide 45% of the benefits (+501 life-years), but would
require CAC screening for all 10,000, which would cost $2.25 million and cause 9 radiation-
induced cancers (Table 1).
With favorable statin assumptions ($0.13/pill and no quality of life penalty), the costs of
statin treatment are low and are almost entirely offset by healthcare savings from prevented
events. Targeted statin prescribing, therefore, would not result in substantial savings, and
would not be a rational alternative to Treat All (Table 1).
Under less favorable assumptions, statin costs ranged from $3.46-$28.91 million, and these
costs were not completely offset by healthcare savings from prevented events; with more
persons treated with statins, both costs and QALYs increased. Treat if CAC>100 and >300
identified relatively small numbers of persons to treat with statins and did not generate
enough QALYs to offset the testing costs compared with competing strategies. In contrast,
Treat if CAC>0 was reasonable (not dominated), producing more QALY's than Treat None
at a cost of $18,000/QALY. Treat All produced even more QALYs, but at a much higher
price ($78,000/QALY, Table 1).
A parallel analysis for 55-year old men at 7.5% CHD risk (stroke risk=1.2%) yielded very
similar results (Supplemental Table 2). Men were more likely to have CAC (39% with
CAC>0), more likely to have a myocardial infarction or stroke and less likely to have angina
as a first event, and generally had lower life expectancy, but incremental cost-effectiveness
ratios were nearly identical ($19,000/QALY for Treat if CAC>0 compared to Treat None;
and $80,000/QALY for Treat All compared to Treat if CAC>0).
Sensitivity analyses for base case scenario
With favorable statin assumptions, Treat All was cost-saving or relatively cost-effective (<
$50,000/QALY) in 55-year-old women with high cholesterol even with wide variation of
other model parameters in one-way sensitivity analyses (Table 2) and with global
probabilistic sensitivity analyses (Figure).
With unfavorable statin assumptions, the Treat if CAC>0 strategy remained relatively cost-
effective (≤$50,000/QALY; see Supplemental Table 3 for ICER values) in one-way
sensitivity analyses that varied the statin myopathy rate, the statin discontinuation rate
(unless it is 75% or greater), statin efficacy (unless it is reduced by 50% or more), CAC scan
costs (unless direct costs are $600 or more), CAC-specific relative risk estimates (unless
they are reduced by 50% or more), the degree of radiation exposure from the CAC scan (up
to 10.5 mSv), or assumptions about the downstream mortality risk after CVD events (Table
2). Preference for the Treat if CAC>0 strategy was somewhat sensitive, however, to global
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probabilistic parameter variation, and very sensitive to society's willingness-to-pay threshold
(Figure).
When statin costs are even higher ($4.00/pill) or disutility larger (0.02, equivalent to trading
away over 10 weeks of perfect health to avoid 10 years on statins), Treat None is preferred
(Table 2).
Alternate clinical scenarios
With favorable statin assumptions and using a willingness-to-pay threshold of $50,000/
QALY, the Treat All strategy was preferred in every clinical scenario that we simulated,
including men and women at lower age and lower risk (Table 3). With less favorable statin
assumptions, the Treat if CAC>0 strategy was preferred in most scenarios where CHD risk
was intermediate (5%-10%), but with some variation by age and sex (Table 3).
Supplemental Tables 4a and 4b provide clinical characteristics, CAC prevalence (and thus
the “yield” of CAC screening in each clinical scenario), and continuous ICER values for
each of these alternate clinical scenarios. Supplemental Tables 5-8 demonstrate shifts in the
window of cost-effectiveness for CAC testing with altered assumptions about statin efficacy,
cost and disutility. A CAC threshold higher than 0 (Treat if CAC>100) was cost-effective
only in edge cases, usually when statin cost or disutility was assumed to be quite high (see
Supplemental Tables 5-8); otherwise the CAC=0 threshold was preferred. Treat if CAC>300
was dominated in every scenario we analyzed.
DISCUSSION
Statins are effective at preventing CHD events across a very broad range of CHD risk1,
including risk levels well below current statin treatment thresholds5, and are considered to
be very safe2, 34. Our results indicate that when they are also inexpensive ($0.13/pill = $4/
month) and easy to use (i.e., no quality of life penalty), obtaining a CAC scan in order to
prevent some patients from having to take a statin is not a cost-effective approach. Under
these assumptions, which represent a likely scenario in the current generic statin era, our
model suggests that it is better not to order the test and instead simply to treat with statins
(“Treat All”).
When statins cost more and/or substantially diminish quality of life, our analyses show that
CAC testing can be a cost-effective way of identifying patients who are at very low CHD
risk and therefore have little to gain from these medications. Our base-case scenario
illustrates such a situation: for a 55-year-old woman with high cholesterol and 10-year CHD
risk of 7.5%, whose insurance would pay $1/pill for her statin prescription and who would
much prefer not to take them (disutility=.00384; i.e., she would be willing to trade 2 weeks
of perfect health to avoid 10 years of statin therapy), our analysis demonstrates that a
strategy of obtaining a CAC scan first and only treating her with statins if the scan
demonstrates some evidence of calcified atherosclerotic plaque (i.e., CAC>0) is relatively
cost-effective. This decision would only be rational, however, if society is willing to pay at
least $18,000/QALY but not over $78,000/QALY. These threshold values, and thus the
potential cost-effectiveness of CAC testing, depend critically on statin assumptions (cost and
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disutility) and on the specifics of the clinical scenario (age, sex, risk factor profile), which
drive both CHD risk and CAC prevalence.
Our results are generally consistent with prior cost-effectiveness analyses. Two recent
analyses20, 21 simulated CAC testing and reclassification of a population of intermediate risk
persons (using two different population/community-based cohort studies) with statin20, 21
and antihypertensive21 treatment intensity based on post-test risk. One assumed inexpensive
statins ($0.13/pill) and found results very consistent with our favorable statin assumptions
scenario (i.e., “Treat All” dominated),20 and the other used higher statin costs ($1.56/pill),
and found cost-effectiveness of CAC screening, at least in men,21 consistent with our
unfavorable statin assumptions scenario. Unlike either of these analyses, ours considered
more focused, specific clinical scenarios instead of averaging results over the entire
intermediate risk population. Our results suggest that the cost-effectiveness of CAC testing
varies, even among persons at intermediate risk, depending on the specifics of the clinical
scenario. Older cost-effectiveness analyses incorporated follow-up ischemia testing after a
positive CAC scan18, 19 (which is not currently recommended12) and used assumptions
about CAC risk stratification that predate MESA and other modern cohort studies,17-19 and
are therefore not directly comparable.
Our results are also consistent with prior cost-effectiveness analyses showing that statin
therapy can be cost-effective even in lower-risk patients, assuming it remains efficacious, if
it is inexpensive and does not significantly reduce quality of life.27, 36, 37 While $4/month
programs available at discount pharmacy outlets should provide access to very low cost
statins, most Americans do not avail themselves of these programs,26 and the costs of even
generic statins are substantially higher at retail pharmacies.27, 36 The decrement in quality of
life associated with statin use is similarly hard to parameterize for cost-effectiveness
modeling. Patients often express a preference not to take statins, which presumably reflects
an expected impact on quality of life; but it is difficult to quantify that impact for any given
individual, and there is wide variation between individuals and within individuals over time
(and with experience and education). Our approach, though imperfect, is consistent with
prior work38 and current guidelines5 that suggest that patient preferences and quality of life
are important to consider when making decisions about statin prescribing and CAC testing.
The cost-effectiveness of CAC testing is also somewhat sensitive to assumptions about the
effectiveness of risk stratification provided by the CAC test. According to our best estimates
from MESA11 (used for these analyses), a previous meta-analysis,39 and recent results from
other cohort studies,40-42 the relative risks associated with high CAC scores are large. With
degradation in those relative risk estimates, CAC testing is no longer cost-effective (Table
2). This degradation might occur if scanning technique and interpretation are lower quality
in practice than they have been in research studies, or if research estimates of CAC
prediction were otherwise over-optimistic, such as might occur from the lack of blinding to
CAC scores that has been common in cohort studies. This sensitivity to assumptions creates
a powerful rationale for real-world effectiveness testing with a clinical trial, as has been
proposed43; such a trial, however, would be very expensive and would take many years to
complete.
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Our finding that the “>0” CAC threshold strategy dominates higher CAC score thresholds is
somewhat surprising. Higher CAC scores are associated with substantially higher relative
risk for CHD (Supplemental Table 1), and anecdotes suggest that higher scores are often
used in clinical practice for decision-making. The low prevalence of high CAC scores,
however, make these high treatment threshold strategies inefficient (i.e., the “number needed
to scan” is too high). While surprising, our findings are consistent with prior commentary on
this issue44.
Our analysis was limited in a number of ways. We used estimates of statin efficacy from a
meta-analysis that included patients with moderately high CHD risk (Supplemental
Material),1 but we applied those efficacy estimates in scenarios where risk is lower and the
evidence for statin therapy effectiveness is less established. Our results were robust to
substantial degradation in statin efficacy, but clearly would not hold if statins were
ineffective in any given scenario. The excess cancer caused by radiation may vary with age,
sex, scan technique and other factors15, 32; and radiation may also induce a small increase in
CHD rates.45 We did not model these intricacies, but our analyses reveal little sensitivity to
this parameter. Given the lower prevalence of CAC in non-White populations46, we would
expect some differences in cost-effectiveness across race/ethnicity, but did not attempt these
analyses. We illustrated our results by indicating which strategy would be preferred if a
simple (and traditional/”mythical”47) willingness-to-pay threshold of $50,000/QALY were
used by policymakers. Some have suggested that a higher threshold is more consistent with
societal values,48 or that using any simple threshold is unrealistic47. We agree, and have
provided continuous ICER values throughout to enable alternate illustrations and
interpretation. We did not attempt to model the possibility that CAC testing might stimulate
statin adherence, or to analyze other uses of CAC testing, such as to guide aspirin or
antihypertensive therapy, to screen symptomatic patients, repeated use over time, etc.
Our cost-effectiveness analysis supports a limited role for CAC testing in asymptomatic
persons. When statins are expected to be effective, safe, and inexpensive, and the patient
does not have a strong preference against taking the medication, our analyses suggest that
the decision to prescribe a statin is relatively straightforward and that CAC testing is neither
necessary nor cost-effective. The decision to use a statin, however, is often difficult for
clinicians and patients. In these settings, the additional information about CHD risk that
CAC testing provides can be worth the additional expense and radiation exposure that comes
with the test.
Supplementary Material
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Figure. Probability of cost-effectiveness of Treat All, Treat None and CAC screening strategies
at different willingness to pay thresholds
These acceptability curves illustrate probabilistic results from 10,000 model runs of the base
case clinical scenario (a 55-year-old woman with high cholesterol), under both favorable and
unfavorable statin assumption scenarios, that account for the uncertainty in parameter
estimates described in Supplemental Table 1. The decision to measure CAC is sensitive to
the willingness to pay threshold when unfavorable assumptions about statins are used. A
disutility of .00384 is equivalent to 2 weeks of perfect health traded away to avoid 10 years
on statins. CAC – Coronary artery calcium score; QALY – Quality-adjusted life-years
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Table 2
One-Way Sensitivity Analyses
Parameter (base-case assumption) Preferred strategy for a 55-year old woman with high cholesterol
*
 if
society is willing to pay up to $50,000/QALY
Favorable statin assumptions:
$0.13/pill and no disutility
†
Less favorable statin assumptions:
$1.00/pill and disutility = .00384
†
Base-case Treat All Treat if CAC>0
Statin price ($0.13 or $1.00/pill)
†




- $0.50 Treat All Treat All
- $1.00 Treat All
Treat if CAC>0
†
- $2.00 Treat if CAC>0 Treat if CAC>0
- $4.00 Treat None Treat None





- .001 Treat All Treat All
- .00384 Treat All
Treat if CAC>0
†
- .0075 Treat All Treat if CAC>0
- .01 Treat if CAC>0 Treat if CAC>0
- .015 Treat if CAC>0 Treat None
- .02 Treat None Treat None
Statin myopathy rate, per person-year (.001)
- .005 Treat All Treat if CAC>0
- .01 Treat All Treat if CAC>0
- .05 Treat All Treat if CAC>0
Statin discontinuation (31%)
- 0% Treat All Treat if CAC>0
- 50% Treat All Treat if CAC>0
- 75% Treat All Treat All
Statin efficacy (0% reduction)
‡
25% increase Treat All Treat if CAC>0
25% reduction Treat All Treat if CAC>0
50% reduction Treat None Treat None
75% reduction Treat None Treat None
CAC scan direct cost ($114.37)
- $100 Treat All Treat if CAC>0
- $250 Treat All Treat if CAC>0
- $400 Treat All Treat if CAC>0
- $600 Treat All Treat All
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Parameter (base-case assumption) Preferred strategy for a 55-year old woman with high cholesterol
*
 if
society is willing to pay up to $50,000/QALY
Favorable statin assumptions:
$0.13/pill and no disutility
†
Less favorable statin assumptions:
$1.00/pill and disutility = .00384
†
Average cost of working up incidental findings from CAC scan
($40.19)
- $0 Treat All Treat if CAC>0
- $100 Treat All Treat if CAC>0
- $250 Treat All Treat if CAC>0
CAC scan relative risks (0% reduction from Detrano 200811)
‡
10% reduction Treat All Treat if CAC>0
25% reduction Treat All Treat if CAC>0
50% reduction Treat All Treat All
75% reduction Treat All Treat All
CAC scan radiation exposure (2.3 mSv)
1 mSv Treat All Treat if CAC>0
5 mSv Treat All Treat if CAC>0
10.5 mSv15 Treat All Treat if CAC>0
All-cause mortality relative risks after CVD events (0%
reduction)
‡
25% reduction Treat All Treat if CAC>0
50% reduction Treat All Treat if CAC>0
75% reduction Treat All Treat if CAC>0
CHD – Coronary heart disease; CVD events – Cardiovascular disease events, including; CAC – Coronary artery calcium; Treat if CAC>X – Test
for CAC, and treat with statins if the CAC score is over X.
*
The base-case clinical scenario is a 55-year-old woman with total cholesterol = 221 mg/dl, HDL cholesterol = 40 mg/dl, systolic blood pressure =
120 mmHg without medications who does not smoke or have diabetes.
†
Indicates base-case scenarios. Statin price and disutility were varied in one-way sensitivity analyses within each scenario to show the independent
contribution of each factor. For one-way analyses where a different parameter is varied, we show results for both favorable and unfavorable statin
assumption scenarios. In the favorable statin assumptions scenario, statins cost $0.13/pill and have no disutility. In the less favorable statin
assumptions scenario, statins cost $1.00/pill and have disutility = .00384, equivalent to 2 weeks of perfect health traded away to avoid 10 years on
statins.
‡
Statin efficacy (relative risk reductions for myocardial infarction, angina, CHD death, and stroke), CAC scan relative risks (for CHD events based
on the CAC score), and all cause mortality relative risks after CVD events (risk of death multipliers in post-CHD and stroke event states) were
varied from the base-case assumptions (see Supplemental Table 1) simultaneously by the % reduction shown, after conversion to the log scale.
Statin efficacy relative risks were also increased in sensitivity analyses given that larger relative risks were observed for lower risk participants in
our meta-analysis source for statin efficacy1.
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